Ajai Chari

13.8k total citations · 4 hit papers
217 papers, 4.7k citations indexed

About

Ajai Chari is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Ajai Chari has authored 217 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Hematology, 109 papers in Molecular Biology and 94 papers in Oncology. Recurrent topics in Ajai Chari's work include Multiple Myeloma Research and Treatments (201 papers), Protein Degradation and Inhibitors (82 papers) and Peptidase Inhibition and Analysis (38 papers). Ajai Chari is often cited by papers focused on Multiple Myeloma Research and Treatments (201 papers), Protein Degradation and Inhibitors (82 papers) and Peptidase Inhibition and Analysis (38 papers). Ajai Chari collaborates with scholars based in United States, Spain and Netherlands. Ajai Chari's co-authors include Sundar Jagannath, Saad Z. Usmani, Hearn Jay Cho, Sagar Lonial, Khalid Mezzi, Nina Shah, Emma Scott, Amrita Krishnan, Samir Parekh and María‐Victoria Mateos and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ajai Chari

205 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

2022 350 citations Ajai Chari, Albert Oriol et al. profile →
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

2020 304 citations Nina Shah, Ajai Chari et al. profile →
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

2016 303 citations Saad Z. Usmani, Brendan M. Weiss et al. Blood profile →
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

2024 51 citations Niels W.C.J. van de Donk, Philippe Moreau et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ajai Chari United States	32	3.4k	2.7k	2.6k	677	584	217	4.7k
Katja Weisel Germany	33	4.3k 1.3×	3.2k 1.2×	3.0k 1.2×	683 1.0×	634 1.1×	335	5.7k
Jeffrey A. Zonder United States	35	2.7k 0.8×	2.9k 1.1×	1.9k 0.7×	390 0.6×	330 0.6×	194	4.6k
Tahamtan Ahmadi United States	27	3.1k 0.9×	2.1k 0.8×	2.6k 1.0×	703 1.0×	938 1.6×	92	4.6k
Helgi van de Velde United States	36	3.0k 0.9×	2.8k 1.1×	3.3k 1.3×	210 0.3×	357 0.6×	166	5.4k
Ivan Špıčka Czechia	24	3.1k 0.9×	2.4k 0.9×	2.1k 0.8×	200 0.3×	249 0.4×	141	3.7k
Thomas Pabst Switzerland	30	2.5k 0.7×	1.6k 0.6×	1.2k 0.5×	219 0.3×	376 0.6×	180	4.3k
Alexander E. Perl United States	37	3.9k 1.2×	3.2k 1.2×	942 0.4×	137 0.2×	488 0.8×	200	6.3k
Jeffrey E. Lancet United States	48	5.3k 1.5×	3.5k 1.3×	1.8k 0.7×	126 0.2×	625 1.1×	437	7.8k
B. Douglas Smith United States	43	4.2k 1.2×	2.8k 1.1×	1.3k 0.5×	103 0.2×	829 1.4×	171	6.3k
Tibor Kovacsovics United States	29	2.3k 0.7×	1.4k 0.5×	880 0.3×	123 0.2×	433 0.7×	123	3.7k

Countries citing papers authored by Ajai Chari

Since Specialization

Citations

This map shows the geographic impact of Ajai Chari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajai Chari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajai Chari more than expected).

Fields of papers citing papers by Ajai Chari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajai Chari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajai Chari. The network helps show where Ajai Chari may publish in the future.

Co-authorship network of co-authors of Ajai Chari

This figure shows the co-authorship network connecting the top 25 collaborators of Ajai Chari. A scholar is included among the top collaborators of Ajai Chari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ajai Chari. Ajai Chari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reyes, Kevin, Yen‐Chun Liu, Chiung‐Yu Huang, et al.. (2024). Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Advances. 8(9). 2207–2216. 15 indexed citations

Nooka, Ajay K., Jonathan L. Kaufman, César A. Rodríguez, et al.. (2024). Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. British Journal of Haematology. 204(6). 2227–2232.

Landgren, Ola, Ajai Chari, Yaël C. Cohen, et al.. (2024). Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 145(15). 1658–1669. 1 indexed citations

Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477. 2 indexed citations

Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2023). Durable MRD and Imaging-Negative Remission ≥ 5 Years Post-Therapy Predicts Long-Term Progression-Free Survival in Multiple Myeloma Patients - a Single-Center Observational Study. Blood. 142(Supplement 1). 1998–1998.

Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations

Auclair, Daniel, Carol Mansfield, Mark A. Fiala, et al.. (2022). Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. SHILAP Revista de lepidopterología. 9 indexed citations

Restrepo, Paula, Sherry Bhalla, Yogita Ghodke‐Puranik, et al.. (2022). A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precision Oncology. 6(6). e2200147–e2200147. 14 indexed citations

Lancman, Guido, Samantha E. Jacobs, John T. Doucette, et al.. (2021). Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(5). e470–e476. 18 indexed citations

10.

Restrepo, Paula, Sherry Bhalla, Adolfo Aleman, et al.. (2021). Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature. Blood. 138(Supplement 1). 457–457. 1 indexed citations

11.

Leng, Siyang, Erin Moshier, Douglas Tremblay, et al.. (2020). Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clinical Lymphoma Myeloma & Leukemia. 20(10). e734–e751. 2 indexed citations

12.

Perumal, Deepak, Naoko Imai, Alessandro Laganà, et al.. (2019). Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research. 26(2). 450–464. 59 indexed citations

13.

Laganà, Alessandro, Violetta V. Leshchenko, Marsha Crochiere, et al.. (2018). E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients. Blood. 132(Supplement 1). 3216–3216. 8 indexed citations

14.

Façon, Thierry, Sagar Lonial, Brendan M. Weiss, et al.. (2017). Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001. Blood. 130. 1824–1824. 15 indexed citations

15.

Lonial, Sagar, Jesús F. San Miguel, Joaquín Martínez‐López, et al.. (2017). Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study. Blood. 130. 1869–1869. 9 indexed citations

16.

Chari, Ajai, Dorothy Romanus, Katarina Luptakova, et al.. (2017). Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience. Blood. 130. 1818–1818. 6 indexed citations

17.

Chari, Ajai, Saad Z. Usmani, Amrita Krishnan, et al.. (2017). Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study. Blood. 130. 3110–3110. 23 indexed citations

18.

Chari, Ajai, et al.. (2017). Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database. Blood. 130. 2190–2190. 3 indexed citations

19.

Auclair, Daniel, Carol Mansfield, Ajai Chari, et al.. (2017). Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach. Blood. 130. 5662–5662. 2 indexed citations

20.

Perumal, Deepak, Violetta V. Leshchenko, Zewei Jiang, et al.. (2016). Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research. 76(5). 1225–1236. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact